- Home
- QTI vs GLTO Comparison
QTI vs GLTO Comparison
Compare QTI & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTI
- GLTO
- Stock Information
- Founded
- QTI 2012
- GLTO 2011
- Country
- QTI United States
- GLTO Denmark
- Employees
- QTI N/A
- GLTO N/A
- Industry
- QTI
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- QTI
- GLTO Health Care
- Exchange
- QTI NYSE
- GLTO Nasdaq
- Market Cap
- QTI 11.2M
- GLTO 12.0M
- IPO Year
- QTI N/A
- GLTO 2020
- Fundamental
- Price
- QTI $0.58
- GLTO $6.94
- Analyst Decision
- QTI
- GLTO Buy
- Analyst Count
- QTI 0
- GLTO 1
- Target Price
- QTI N/A
- GLTO $10.00
- AVG Volume (30 Days)
- QTI 77.9K
- GLTO 44.9K
- Earning Date
- QTI 11-26-2024
- GLTO 11-04-2024
- Dividend Yield
- QTI N/A
- GLTO N/A
- EPS Growth
- QTI N/A
- GLTO N/A
- EPS
- QTI N/A
- GLTO N/A
- Revenue
- QTI $3,105,806.00
- GLTO N/A
- Revenue This Year
- QTI N/A
- GLTO N/A
- Revenue Next Year
- QTI N/A
- GLTO N/A
- P/E Ratio
- QTI N/A
- GLTO N/A
- Revenue Growth
- QTI 15334.88
- GLTO N/A
- 52 Week Low
- QTI $0.41
- GLTO $6.55
- 52 Week High
- QTI $14.40
- GLTO $23.50
- Technical
- Relative Strength Index (RSI)
- QTI 44.99
- GLTO 27.49
- Support Level
- QTI $0.55
- GLTO $6.61
- Resistance Level
- QTI $0.65
- GLTO $7.50
- Average True Range (ATR)
- QTI 0.07
- GLTO 0.62
- MACD
- QTI -0.01
- GLTO -0.31
- Stochastic Oscillator
- QTI 13.88
- GLTO 6.67
About QTI QT IMAGING HOLDINGS INC
QT Imaging Holdings Inc is engaged in the research, development and commercialization of an automated breast imaging system producing high-resolution transmission ultrasound images.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.